Handelsbanken Fonder AB Has $290,000 Stock Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Handelsbanken Fonder AB boosted its holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 26.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,100 shares of the biotechnology company’s stock after purchasing an additional 4,900 shares during the quarter. Handelsbanken Fonder AB’s holdings in Rocket Pharmaceuticals were worth $290,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Rocket Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 582 shares in the last quarter. Rhumbline Advisers raised its position in Rocket Pharmaceuticals by 1.3% in the 4th quarter. Rhumbline Advisers now owns 99,339 shares of the biotechnology company’s stock valued at $1,249,000 after buying an additional 1,242 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Rocket Pharmaceuticals by 1.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,633 shares of the biotechnology company’s stock worth $2,210,000 after purchasing an additional 1,561 shares during the last quarter. Pier 88 Investment Partners LLC grew its position in Rocket Pharmaceuticals by 5.1% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 32,490 shares of the biotechnology company’s stock worth $600,000 after purchasing an additional 1,590 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Rocket Pharmaceuticals by 9.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,767 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 1,675 shares during the last quarter. Institutional investors and hedge funds own 98.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $29.00 target price on the stock. Chardan Capital cut their price objective on Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating on the stock in a research report on Friday. Wedbush started coverage on Rocket Pharmaceuticals in a research note on Monday, December 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Canaccord Genuity Group decreased their price target on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research note on Monday. Finally, Leerink Partners dropped their price objective on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Rocket Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $42.30.

Rocket Pharmaceuticals Stock Down 7.0 %

Rocket Pharmaceuticals stock opened at $8.79 on Tuesday. Rocket Pharmaceuticals, Inc. has a 1-year low of $8.78 and a 1-year high of $30.94. The firm has a 50 day simple moving average of $10.89 and a 200 day simple moving average of $14.66. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $801.27 million, a price-to-earnings ratio of -3.20 and a beta of 0.98.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.06. On average, analysts predict that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.